MacroGenics (MGNX)
Develops engineered antibody therapies for cancer through internal programs and collaborations.
Something off on this page? Send us feedback.
Develops clinical-stage cancer therapies using engineered antibodies, bispecific DART molecules, and antibody-drug conjugates. The business combines internal programs with collaborations, royalties, and selected asset transactions.
Builds clinical-stage oncology programs around Fc-engineered antibodies, bispecific DART molecules, and antibody-drug conjugates. Current internal programs include MGC026, MGC028, and lorigerlimab, alongside collaborations spanning commercial, clinical, and preclinical work.
Operations are rooted in Rockville, Maryland and concentrate on research and development following the sale of GMP manufacturing operations and the CDMO business. Global MARGENZA rights were sold to TerSera, while partnership economics include ZYNYZ royalties and collaborations with Incyte, Sanofi, and Gilead.
Progress depends on clinical data, regulatory actions, collaboration milestones and royalties, and external manufacturing and supply arrangements following the Bora transaction.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Apr 20, 2026 | Barclays | Reiterate | Rating: —Target: $3 | Target: $6 |
| Apr 10, 2026 | B. Riley Securities | Upgrade | ||
| Nov 7, 2024 | JMP Securities | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $173.3M · Total debt $35.1M · Total assets $345.4M · Shareholders' equity $42.9M
- Revenue
- $32.8M
- Operating income
- −$13.9M
- Net income
- $19.5M
No dividends on record.
| Institutions | ≈ 76.74% | 48.89M shares | |
|---|---|---|---|
| 129 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 3.31% | 2.11M shares | |
| 16 holders · as of Aug 18, 2026 | |||
| Other | ≈ 19.95% | 12.70M shares | |
| remainder | |||
63.70M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
T. Rowe Price Investment Management, Inc.Institution | 8.85% | 5.64M | filed Feb 14, 2024 |
Armistice Capital, LLCInstitution | 7.86% | 5.01M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 7.35% | 4.68M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 4.17% | 2.66M | as of Jun 30, 2026 |
Renaissance Technologies LLCInstitution | 4.13% | 2.63M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 19, 2026 | Jeffrey Stuart Peters | officer: Senior VP, GC, and Secretary | −31,105 | $4.15 |
- Gilead Sciences
Trop-2, topoisomerase-I ADC therapy for solid tumors
- Pfizer
Seagen-derived solid-tumor ADC and bispecific capabilities
- Genmab (ADR)
Solid-tumor ADC and bispecific-antibody platform overlap
- BioNTech (ADR)
Solid-tumor bispecific and ADC-development overlap
- Amgen
Approved solid-tumor BiTE therapy and broader T-cell-engager platform
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| MacroGenics | $4.12 | 0.00% | $261.9M | — | — | 1.6 | +47.6% |
| Gilead Sciences | $152.24 | +1.12% | $186.93B | — | 16.8 | 6.1 | +10.2% |
| Pfizer | $27.77 | +0.09% | $158.10B | 36.7 | 9.9 | 2.5 | +2.6% |
| Genmab (ADR) | $34.94 | +0.71% | $21.30B | 27.3 | 26.7 | 5.2 | +24.9% |
| BioNTech (ADR) | $100.28 | +2.33% | $24.62B | — | — | 8.1 | −60.7% |
| Amgen | $407.38 | +3.62% | $212.19B | 24.4 | 17.4 | 5.6 | +9.7% |
| Median | 27.3 | 17.1 | 5.6 | +9.7% |